Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Capricor Therapeutics (CAPR) EPS (Weighted Average and Diluted) (2016 - 2025)

Capricor Therapeutics has reported EPS (Weighted Average and Diluted) over the past 9 years, most recently at -$0.62 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.62 for Q4 2025, down 463.64% from a year ago — trailing twelve months through Dec 2025 was -$2.26 (down 96.52% YoY), and the annual figure for FY2025 was -$2.26, down 96.52%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.62 at Capricor Therapeutics, down from -$0.54 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for CAPR hit a ceiling of $0.02 in Q4 2023 and a floor of -$0.62 in Q4 2025.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.3 (2022), compared with a mean of -$0.31.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): surged 106.45% in 2023 and later plummeted 650.0% in 2024.
  • Capricor Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.26 in 2021, then dropped by 19.23% to -$0.31 in 2022, then soared by 106.45% to $0.02 in 2023, then plummeted by 650.0% to -$0.11 in 2024, then tumbled by 463.64% to -$0.62 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.62 (Q4 2025), -$0.54 (Q3 2025), and -$0.57 (Q2 2025) per Business Quant data.